TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

Related Keywords

Germany ,Helsinki ,Eteläuomen Läi ,Finland ,Boston ,Massachusetts ,United States ,American ,Finnish ,Akseli Hemminki ,Aino Kalervo ,Daniel Gooch ,Us Department Of Defense ,Merck Kgaa ,Merck Co Inc ,Merck Sharp Dohme ,European Innovation Council ,University Of Helsinki ,American Association For Cancer Research ,Scius Communications ,Merck Kga ,Results Reveal Mechanism ,Correlative Analyses ,American Association ,Cancer Research ,Annual Meeting ,Merck Sharp ,Lifeline Ventures ,Finnish Industry Investment ,Business Finland ,Tilt ,Cancer Therapy ,Iotherapeutics ,Ovarian Cancer ,Merck Co ,Nc ,Dancer ,Oncolytic Viruses ,Clinical Response ,Phasei Clinical Trial ,Cancer Cells ,Keytruda ,Biotechnology Company ,